Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Amyris Is Soaring Today

By Maxx Chatsko – Updated Apr 26, 2019 at 10:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The industrial biotech has punched its ticket to the cannabis party, but investors shouldn't get too excited just yet.

What happened

Shares of Amyris (AMRS 11.30%) rose nearly 50% today after the company announced it had signed a development, licensing, and commercialization agreement for a cannabinoid ingredient. The specific partner, cannabinoid ingredient, and timing weren't disclosed, but the industrial biotech said the deal includes $255 million in milestone payments and the potential to receive royalty payments. 

Some of the announced bounty will be received up front, while the remainder can be earned for hitting certain milestones in the next one to three years. Considering Amyris sported a market cap of $240 million at Monday's close, Wall Street is cheering the idea that it might be able to earn $255 million in milestone payments in the near future -- and enter an exciting new industry, no less.

As of 11:18 a.m. EST on Tuesday, the stock had settled to a 35.1% gain.

An arrow bouncing up shelves on a wall.

Image source: Getty Images.

So what

Cannabinoids are typically harvested from growing cannabis plants. But agriculture and genetically modified plants aren't always the most efficient methods for producing large quantities of product. Growing cannabis plants is time-consuming, takes up a considerable footprint, requires significant controls to reduce contamination, and doesn't always result in a homogeneous product. Processing plant material to extract the useful product can be inefficient and accompanied by low yields.

That's why a number of companies are exploring the use of industrial biotech as an alternative production process. On paper, it's possible to port over the metabolic pathway that allows a plant to create cannabinoid compounds into an industrial microbe such as yeast. The microbe can be grown in a large bioreactor by fermentation, the cells can be harvested once they reach a sufficient density, and the cannabinoid compound of interest can be purified after that. The full-process turnaround time is less than two weeks -- allowing more product to be produced in a smaller footprint year-round.

In reality, industrial biotech has struggled to launch with highly engineered microbes. Cannabinoid compounds might hit the right sweet spot of selling price and market size to make it all work, but they're relatively complex molecules that will be difficult to make at spec. That hasn't made cannabis companies any less curious though.

A Canadian start-up named Hyasynth Biologicals began developing industrial microbes to produce cannabinoid compounds years ago (before it was cool). It's a licensed dealer under the Narcotic Control Regulations of Health Canada and has received investment from cannabis company OrganiGram Holdings. Others have piled onto the trend only recently. Ginkgo Bioworks, an analytic lab specializing in engineered microbes, signed a deal with Cronos for specific cannabinoid compounds. Intrexon announced a vague unpartnered project last summer. And now Amyris is getting in on the action.

Check out the latest Amyris earnings call transcript.

A stainless steel bioreactor.

A stainless-steel bioreactor in a pilot facility: a future source of cannabinoids? Image source: Getty Images.

Now what

The promise of producing cannabinoid compounds through fermentation cannot be dismissed entirely. It could be an important product for the fledgling and struggling field of synthetic biology and create significant value for cannabis companies. However, aside from Hyasynth Bio, the biotech players piling onto the trend lately have each struggled to follow through on major partnerships and to commercialize products. Amyris may be the worst offender.

In recent years it has told investors about big plans for malaria treatments, renewable transportation fuels, polymers, lubricants, solvents, direct-to-consumer hand cleaners, pharmaceutical ingredients, zero-calorie sweeteners, cosmetics, and now cannabinoid compounds. It hasn't delivered much success to date, so investors will want to remain grounded despite the latest announcement.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool recommends OrganiGram Holdings. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amyris, Inc. Stock Quote
Amyris, Inc.
$3.25 (11.30%) $0.33
Precigen, Inc. Stock Quote
Precigen, Inc.
$2.02 (-4.72%) $0.10
Cronos Group Stock Quote
Cronos Group
$2.93 (3.90%) $0.11
OrganiGram Holdings Stock Quote
OrganiGram Holdings
$0.90 (3.26%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.